Recent Posts on This Topic | See All >
Scottsdale Healthcare-TGen clinical trial results signal advances against skin cancerTags: cancer, scottsdale healthcare, tgen
[Source: TGen] - Analyses of clinical trial results published today in the New England Journal of Medicine (NEJM) shows a potential new investigational therapy for advanced and metastatic basal cell skin cancer.
The study, conducted at TGen Clinical Research Service (TCRS) at Scottsdale Healthcare and two other sites appears to demonstrate tumor shrinkage and limited side effects. TCRS is a strategic alliance between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.
These findings are significant because no proven therapy exists for advanced basal cell carcinoma (BCC). BCC is the most common cancer in the United States with about one million new cases diagnosed each year. Arizona has one of the highest incidences of skin cancer in the world.
The article appears on-line today and in the Sept. 17 print issue of NEJM.
For more information: Scottsdale Healthcare-TGen clinical trial results signal advances against skin cancer
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.